<DOC>
	<DOCNO>NCT01758458</DOCNO>
	<brief_summary>This phase I/II trial study side effect best way give laboratory treat autologous T cell together aldesleukin see well work treat patient merkel cell carcinoma spread primary site ( place start ) place body . Biological therapy , cellular adoptive immunotherapy , may stimulate immune system different way stop tumor cell grow . Aldesleukin may stimulate white blood cell kill tumor cell . Giving cellular adoptive immunotherapy aldesleukin may better treatment metastatic merkel cell carcinoma .</brief_summary>
	<brief_title>Viral Oncoprotein Targeted Autologous T Cell Therapy Merkel Cell Carcinoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety potential toxicity associate treat patient metastatic merkel cell carcinoma ( MCC ) combine myosin heavy chain ( MHC ) up-regulation therapy adoptive transfer merkel cell polyomavirus ( MCPyV ) T-antigen ( TAg ) -specific polyclonal autologous cluster differentiation ( CD ) 8+ T cell . II . Determine antitumor efficacy associate treat patient metastatic MCC combine MHC up-regulation therapy adoptive transfer MCPyV TAg-specific polyclonal autologous CD8+ T cell . SECONDARY OBJECTIVES : I . Determine vivo persistence evaluable , migration tumor site adoptively transfer polyclonal CD8+ T cell target MCPyV TAg . II . Determine vivo functional capacity adoptively transfer polyclonal CD8+ T cell target MCPyV TAg . OUTLINE : Patients undergo radiation therapy recombinant interferon beta intralesional injection within day -3 day -1 . Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine intravenously ( IV ) day 1 aldesleukin subcutaneously ( SC ) every 12 hour day 1-14 . Treatment repeat least every 28 day 2 course absence disease progression unacceptable toxicity . Patients continue presence detectable metastatic disease 8 week first infusion may repeat treatment regimen include radiation therapy recombinant interferon beta injection . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histopathological documentation MCC concurrent diagnosis metastatic disease Evidence MCPyV TAg tumor expression Available peptideMHC pair fold tetramer MCPyV TAgspecific cell generate reactivity cell line express MCPyV TAg correspond human leukocyte antigen ( HLA ) Bidimensionally measurable disease palpation , clinical exam , radiographic imaging ( xray , compute tomography [ CT ] scan , positron emission tomography [ PET ] scan , magnetic resonance image [ MRI ] , ultrasound ) At least 3 week must pass since follow : systemic corticosteroid , immunotherapy ( example , interleukin , MCC vaccine , intravenous immunoglobulin , expand polyclonal tumor infiltrate lymphocyte [ TIL ] lymphokineactivated killer [ LAK ] therapy ) , pentoxifylline , small molecule chemotherapy cancer treatment , investigational agent agent target merkel cell carcinoma Cardiac ejection fraction &gt; = 40 % ( multigated acquisition [ MUGA ] echocardiogram ) ; patient significant risk factor coronary artery disease ( CAD ) ( include family history , hypertension , and/or dyslipidemia ) , age &gt; 50 , stress echo stress thallium testing require Unable generate antigenspecific MCPyV TAgspecific CD8+ T cell infusion Active infection prior receive study treatment systemic infection require chronic maintenance suppressive therapy Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 White blood cell ( WBC ) &lt; 2000/mcl Hemoglobin ( Hb ) &lt; 8 g/dL Absolute neutrophil count ( ANC ) &lt; 1000/mcl Platelets &lt; 50,000/mcl New York Heart Association functional class IIIIV heart failure , symptomatic pericardial effusion , stable unstable angina , symptom coronary artery disease , congestive heart failure , clinically significant hypotension , ejection fraction = &lt; 40 % ( echocardiogram MUGA ) Clinically significant pulmonary dysfunction , determine medical history physical exam ; patient identify undergo pulmonary function test forced expiratory volume one second ( FEV1 ) &lt; 2.0 L diffuse capacity lung carbon monoxide ( DLCO ) ( correct hemoglobin [ Hgb ] ) &lt; 50 % exclude Creatinine clearance &lt; 30 ml/min attribute MCC metastasis Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 5 x upper limit normal ( ULN ) Bilirubin &gt; 3 x ULN attribute MCC metastasis Active autoimmune disease ( e.g . systemic lupus erythematosus , vasculitis , infiltrate lung disease , inflammatory bowel disease ) whose possible progression treatment would consider unacceptable investigator Symptomatic untreated central nervous system ( CNS ) metastasis ; however , patient 12 asymptomatic , less 1 cm brain/CNS metastasis without significant edema may consider treatment ; subcentimeter CNS lesion note study entry , repeat imaging perform 4 week elapse last scan Any condition organ toxicity deem principal investigator ( PI ) attend physician place patient unacceptable risk treatment protocol Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception abstinence ; woman childbearing potential must negative pregnancy test within two week prior entry Clinically significant ongoing immune suppression include , limited , systemic immunosuppressive agent cyclosporine corticosteroid , chronic lymphocytic leukemia ( CLL ) , uncontrolled human immunodeficiency virus ( HIV ) infection , solid organ transplantation Patients may treatment cancer aside include protocol ; patient may undergo another form treatment concurrently study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>